AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AstraZeneca is conducting a study titled Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM. The study aims to evaluate the effectiveness of a fixed-dose combination (FDC) of Dapagliflozin and Metformin extended-release (XR) compared to their co-administration in managing glycemic control, patient satisfaction, and adherence among Chinese patients with Type 2 Diabetes Mellitus (T2DM).
The intervention being tested is the FDC of Dapagliflozin/Metformin XR, marketed as Xigduo XR. This combination seeks to improve glycemic control by leveraging the complementary mechanisms of the two drugs.
The study is designed as a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label trial. Participants are randomly assigned to either the FDC regimen or co-administered dual therapy, with the primary aim of treatment.
The study began on March 15, 2024, and is currently active but not recruiting. The last update was submitted on June 24, 2025. These dates are crucial as they mark the study’s progress and ensure stakeholders are informed of its status.
This study could significantly impact AstraZeneca’s market position by potentially validating a more effective treatment regimen for T2DM, which may enhance investor confidence. The success of this study could also influence the competitive landscape, as other companies may need to adjust their strategies in response to these findings.
The study is ongoing, and further details are available on the ClinicalTrials portal.